Synribo

Chemical Nameomacetaxine mepesuccinate
Dosage FormInjection (subcutaneous; 3.5mg)
Drug ClassAntineoplastics
SystemBlood
CompanyTeva Pharmaceuticals USA, Inc.
Approval Year2012

Indication

  • For the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).
Last updated on 5/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Synribo (omacetaxine mepesuccinate) Prescribing Information2012Teva Pharmaceuticals USA Inc., North Wales, PA
Document TitleYearSource
Chronic myeloid leukemia, version 2.2021.2020Journal of the National Comprehensive Cancer Network